Supplementary Tables S1 to S4 from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
Year: 2023
Type: supplementary-materials
Abstract: Table S1. P values of comparing time to endpoint survival among all treatment groups in the LNCaP xenograft study Table S2. Summary of PSMA IHC in xenograft tumors Table S3. P values of comparing time to endpoint survival among all treatment groups in the CWR22Rv1 xenograft study Table S4. P values of comparing time to endpoint survival among all treatment groups in PC-3 xenograft study
Authors: Song Cho, Francesca Zammarchi, David G. Williams, Carin E.G. Havenith, Noel R. Monks, Peter Tyrer, Francois D'Hooge, Ryan Fleming, Kapil Vashisht, Nazzareno Dimasi, Francois Bertelli, Simon Corbett, Lauren Adams, Halla W. Reinert, Sandamali Dissanayake, Charles E. Britten, Wanda King, Karma Dacosta, Ravinder Tammali, Kevin Schifferli, Patrick Strout, Martin Korade, Mary Jane Masson Hinrichs, Simon Chivers, Eva Corey, He Liu, Sae Kim, Neil H. Bander, Philip W. Howard, John A. Hartley, Steve Coats, David A. Tice, Ronald Herbst, Patrick H. van Berkel
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362534841